“We’re pleased and proud to report our latest paper using Bio-Hermes-001 data has been published in Alzheimer’s & Dementia. Many thanks to the co-authors who helped to bring this research article to light including Richard Mohs, Douglas Beauregard, Lynne Hughes, Cyndy Cordell, Allan Levey, M.D., Ph.D., Saima Rathore, Nicholas Seyfried, Erik Johnson, Jessie Nicodemus-Johnson, Joshua Christensen, and Robin Wolz
This paper challenges the amyloid-only view of Alzheimer’s pathology by examining biomarker profiles in individuals with clinical signs and symptoms consistent with MCI or Alzheimer’s disease yet were amyloid PET–negative. These participant profiles showed no evidence of subclinical amyloid or tau pathology, yet demonstrated markedly elevated neurofilament light (NfL) levels—consistent with active neurodegeneration of unclear underlying pathology.
Comprehensive proteomic analysis revealed no differentially regulated proteins distinguishing this group from cognitively normal, amyloid PET–negative individuals. In contrast, multiple protein changes were associated with amyloid positivity, which is consistent with prior findings from Emory University ”Plasma proteomic associations with Alzheimer’s disease endophenotypes,” which was published in Nature Aging.
Together, these results highlight that neurodegeneration can occur in the absence of amyloid pathology. Advancing care will require biomarker-informed frameworks that move beyond amyloid-centric models to better understand underlying disease biology and inform future treatment development.” GAP President John Dwyer
To read the paper visit: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71085?af=R